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The coevolution of humans and infectious agents has exerted selective pressure on the 
immune system to control potentially lethal infections. Correspondingly, pathogens have 
evolved with various strategies to modulate and circumvent the host’s innate and adaptive 
immune response. 
 
Schistosoma 
 
species are helminth parasites with genes that have been 
selected to modulate the host to tolerate chronic worm infections, often for decades, 
without overt morbidity. The modulation of immunity by schistosomes has been shown to 
prevent a range of immune-mediated diseases, including allergies and autoimmunity. 
Individual immune-modulating schistosome molecules have, therefore, therapeutic potential 
as selective manipulators of the immune system to prevent unrelated diseases. Here we show 
that 
 
S. mansoni
 
 eggs secrete a protein into host tissues that binds certain chemokines and 
inhibits their interaction with host chemokine receptors and their biological activity. The 
purified recombinant 
 
S. mansoni
 
 chemokine binding protein (smCKBP) suppressed 
inflammation in several disease models. smCKBP is unrelated to host proteins and is the first 
described chemokine binding protein encoded by a pathogenic human parasite and may have 
potential as an antiinflammatory agent.
 
Schistosoma mansoni
 
 is a trematode parasite that
infects humans. Infection of man involves initial
skin penetration by cercariae that migrate, via
the lungs, to develop into adult male and egg-
laying female worms that may reside for up to
10 yr within the mesenteric vasculature. To
achieve such chronic infections, schistosomes
are particularly adept at manipulating the host’s
immune system to the benefit of the parasite
(1). This balanced host–parasite relationship
ensures 
 
 
 
10% of infected individuals develop
severe disease. This close relationship between
schistosomes and the host is illustrated by the
granulomatous inflammation around parasite
eggs trapped in various organs, which, though
a major cause of pathology, is evoked by the
parasite to facilitate the expulsion of its eggs
from the host. Thus, 
 
S. mansoni
 
–infected mice
with compromised immunity (e.g., CD4
 
 
 
 cell
depleted) fail to excrete eggs in the feces, and
 
S. mansoni
 
–infected HIV
 
 
 
 patients with low
CD4
 
 
 
 cell counts have impaired egg excretion
(2, 3).
There is a spectrum of mechanisms whereby
various pathogens can modulate the immune sys-
tem. A currently unique aspect of viral immune
evasion is modulation of cellular recruitment and
activation via the virus-producing secreted
chemokine binding proteins (CKBPs) that bind
and neutralize chemokines (4–7). CKBPs are un-
related to host chemokine receptors and have not
been identified to date in human hosts or other
pathogens. In view of the dynamic selective
modulation of local cell recruitment within the
host by 
 
S. mansoni
 
, we addressed whether this
parasite also produces CKBPs.
 
RESULTS AND DISCUSSION
 
All the life cycle stages of 
 
S. mansoni
 
 that develop
in man were tested for the presence of CKBP
in a cross-linking assay. Using 
 
125
 
I-CXCL8
(IL-8) or 
 
125
 
I-CCL3 (MIP-1
 
 
 
) as target che-
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mokines, we detected a single 
 
 
 
44 kD complex in schisto-
some egg secretions (ES) but not in other life cycle stages
(Fig. 1 A). The 
 
 
 
44 kD complex from ES indicates that, af-
ter subtraction of the chemokine mass (
 
 
 
8 kD), an 
 
 
 
36 kD
CKBP is secreted by schistosome eggs (
 
S. mansoni 
 
CKBP
[smCKBP]). ES and no other parasite stages inhibited the
binding of 
 
125
 
I-CXCL8 or 
 
125
 
I-CCL3 to chemokine recep-
tors expressed in U937 cells in a dose-dependent manner
(Fig. 1 B). Cation exchange chromatography was used to
purify a fraction containing an 
 
 
 
36 kD doublet that specifi-
cally bound 
 
125
 
I-CXCL8 or 
 
125
 
I-CCL3 forming an 
 
 
 
44 kD
complex with 
 
125
 
I-chemokine after cross-linking (Fig. 1 C).
The CKBP in 
 
S. mansoni
 
 eggs is produced by eggs from the
two other major schistosome species that infect man, 
 
S. hae-
matobium
 
 and 
 
S. japonicum
 
 (Fig. 1 D). Despite smCKBP be-
ing detectable in antigen extractions from eggs from the
three schistosome species by Western blotting (Fig. 1 D), we
could detect no chemokine binding activity using these
whole egg antigen preparations (Fig. 1, A and B, and not de-
picted). smCKBP is present in egg homogenates at low con-
centrations; in 1 mg of soluble egg antigen protein there is
 
 
 
10 
 
 
 
g of smCKBP, whereas there is 
 
 
 
150 
 
 
 
g of smCKBP
in 1 mg of ES protein. However, when smCKBP was puri-
fied and concentrated from 
 
S. mansoni
 
 egg antigens, it bound
chemokines (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20050955/DC1).
A proteomic approach was used to identify the gene en-
coding smCKBP. Each of the two bands of 
 
 
 
36 kD (Fig. 2
A) were excised from an SDS-PAGE gel for mass spectrom-
etry and peptide sequence analysis. The two bands were
confirmed to be the same protein with both bands having
the same peptide mass and fragmentation patterns, indicating
that the difference in size is caused by posttranslational mod-
ification of the protein. One of the smCKBP peptides ob-
tained (ITGLGHGTCIDDFTK) was found to match an
expressed sequence tag (EST; available from GenBank/
EMBL/DDBJ under accession no. AI820476) clone from an
 
S. mansoni
 
 egg cDNA library, and its entire nucleotide se-
quence was determined. Despite having chemokine-binding
activity, smCKBP shares no amino acid sequence similarity
to known viral CKBPs or mammalian proteins. As smCKBP
was initially identified in eggs isolated from mouse liver, we
have confirmed that smCKBP is an 
 
S. mansoni
 
–specific gene,
as it is amplified by PCR from genomic DNA prepared from
schistosome cercariae from snails but not from mouse DNA
(unpublished data). Recently, the same 
 
S. mansoni
 
 gene
(available from GenBank/EMBL/DDBJ under accession no.
AY028436) was expressed in 
 
Escherichia coli
 
 and the recombi-
nant protein was shown to induce human basophil degranu-
lation (8); however, we have not seen this activity in insect
cell–expressed smCKBP (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20050955/DC1). The
open reading frame present in the cDNA was expressed with
a COOH-terminal 6xHis tag using the baculovirus and vac-
cinia virus expression systems. In both systems, the recombi-
nant protein (r-smCKBP) was secreted as a doublet of 
 
 
 
32
kD in size, smaller than the 
 
 
 
36 kD natural molecule, with
anti-smCKBP rabbit sera recognizing the natural and recom-
binant protein and both bound chemokines (Fig. 2 A and
not depicted). Purified r-smCKBP expressed in the baculo-
virus system was used in further experiments. Binding assays
confirmed that r-smCKBP specifically bound 
 
125
 
I-CXCL8,
 
125
 
I-CCL3, and 
 
125
 
I-CX3CL1 (fractalkine; Fig. 2 B). More
extensive competition assays with 10 cold competitor che-
mokines showed that r-smCKBP also binds CCL2 (MCP-1)
and CCL5 (regulated on activation, normal T cell expressed
and secreted; unpublished data). smCKBP is glycosylated,
with the difference in size between native (
 
 
 
36 kD) and
r-smCKBP (
 
 
 
32 kD) a reflection of differences in glycosyl-
ation after insect cell expression. Despite the differences in
Figure 1. Presence of a CKBP in S. mansoni ES. (A) Cercarial homoge-
nates (1) or homogenates (2, 4, and 6) or secretions (3, 5, and 7) from schisto-
somula (2 and 3), worms (4 and 5), or eggs (6 and 7) or binding media (8) 
were cross-linked to 125I-CXCL8 or 125I-CCL3. All schistosome antigen prepara-
tions had nonspecific binding (*) to iodinated chemokines (55–60 kD) that 
was also detectable in the binding media. (B) CXCL8 and CCL3 binding to 
U937 cells in the presence of a range of protein concentrations of homog-
enates (open circles and dotted line) or secretions (closed circles and con-
tinuous line) from different life cycle stages of S. mansoni. (C) Cross-
linking of 125I-CXCL8 or 125I-CCL3 to binding media (1 and 4) or smCKBP 
in the absence (2 and 5) or presence (3 and 6) of excess unlabeled che-
mokine. (D) Anti-smCKBP rabbit sera probe of Western blot of homoge-
nates of S. mansoni cercariae (1), schistosomula (2), worms (3), and eggs 
(4), S. japonicum eggs (5), S. haematobium eggs (6), or secretions from
S. mansoni schistosomula (7), worms (8), or eggs (9). 
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size, the ability of smCKBP to bind chemokines was glycan
independent, with deglycosylated natural smCKBP or bacu-
lovirus-expressed r-smCKBP remaining completely bioac-
tive in binding CXCL8 and blocking its activity (unpub-
lished data). r-smCKBP also inhibited the specific binding of
 
125
 
I-CXCL8 or 
 
125
 
I-CCL3 to U937 cells (Fig. 2 C). The bi-
ological function of r-smCKBP was also determined by its
ability to block the CXCL8-elicited migration of human
neutrophils in a chemotaxis assay (Fig. 2 D). In contrast, a
control baculovirus-expressed and 6xHis-tagged protein, a
truncated variant of the ectromelia virus–encoded tumor ne-
crosis factor receptor CrmD (CRD), containing only two
cysteine rich domains (9) and purified according to the same
protocol as for r-smCKBP did not alter chemokine binding
or biological activity (Fig. 2, C and D). r-smCKBP activity
was chemokine specific, as it did not block migration in-
duced by the bacterial chemotactic peptide 
 
N
 
-formyl-
methionyl-leucyl-phenylalanine (n-FMLP; Fig. 2 D).
r-smCKBP also dose-dependently inhibited calcium mobili-
zation after CCL5 activation of human PBMCs, with the
control protein CRD not inhibiting chemokine-induced
cell activation (Fig. 2 E). Natural smCKBP was also func-
tional, with comparable potency as r-smCKBP in blocking
chemokine function in vitro (unpublished data). These re-
sults indicated that smCKBP binds to certain chemokines
and prevents their interaction with specific cellular receptors,
activation of cells, and the migration of cells.
As several important human diseases are associated with
inappropriate activation of chemokines (10), any molecule
that can specifically block chemokine activity has potential
use as a therapeutic (11). Because initial functional data on
smCKBP chemokine-binding activity involved in vitro
studies (Figs. 1 and 2), we have evaluated its role in vivo. In
a murine air pouch model, mice that had been given an in-
travenous injection of r-smCKBP had significantly reduced
CXCL8-induced neutrophil infiltration (P 
 
 
 
 0.001; Fig. 3
A). Interestingly, r-smCKBP did not block eosinophil infil-
tration of the air pouch induced by CCL11 (eotaxin), which
was consistent with smCKBP being unable to bind CCL11
in cross-linking studies (unpublished data). In a contact hy-
persensitivity model, hapten-sensitized mice treated with
r-smCKBP had significantly reduced ear swelling 24 h after
challenge (P 
 
 
 
 0.001; Fig. 3 A). The extent of inhibition of
inflammation was evident on examination of cross sections
of ears from r-smCKBP–treated mice (Fig. 3 B). Isolation of
the inflammatory infiltrate from the hapten-treated ears
showed that r-smCKBP–treated mice were devoid of the
marked neutrophilia observed in cells isolated from the ears
of the control mice (Fig. 3 C). We have also tested the effect
of treatment of mice with r-smCKBP while undergoing ex-
perimental autoimmune encephalomyelitis or arthritis. In
both chronic inflammatory models, r-smCKBP treatment
had no effect on modulating disease (Fig. S3, available at
http://www.jem.org/cgi/content/full/jem.20050955/DC1).
Therefore, smCKBP has specific in vivo activity in suppres-
sion of immediate or local inflammation, which is consistent
with its bioactivity within the egg granuloma, as described
later in this section.
Data on administering r-smCKBP in vivo indicated a
preferential effect on CXCL8 and neutrophils (Fig. 3, A and
B). As antagonism of CXCL8 and neutrophilia is a potential
therapeutic strategy for pulmonary diseases (10, 11), we
evaluated whether r-smCKBP could suppress CXCL8-
induced pulmonary inflammation and resulting compromised
Figure 2. r-smCKBP is a functional CKBP. (A) Silver-stained SDS-PAGE 
gel of natural or r-smCKBP. Western blot of SDS-PAGE resolved natural 
(line 1) and r-smCKBP (line 2) probed with anti-smCKBP antisera or NRS. 
(B) r-smCKBP was cross-linked to 125I-chemokines with or without competing 
cold chemokines. (C) Binding of 125I-CXCL8 and 125I-CCL3 to U937 cells 
after preincubation with r-smCKBP (red filled circles and line) or with a 
control protein (CRD, open circles and continuous line). (D) Migration of 
human neutrophils in response to CXCL8 preincubated with r-smCKBP 
(red bars) or with control CRD (open bars). Migration was also elicited with 
100 nM n-FMLP preincubated with 1,000 ng/ml of r-smCKBP or CRD. The 
values shown represent means   SD from triplicate samples. (E) CCL5-
induced activation (Ca2  flux) of human PBMCs from three donors treated 
with r-smCKBP (red filled circles and line) or control CRD (open circles and 
continuous line). Data are representative of two to four separate experiments. 
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lung function. Mice treated intranasally with CXCL8 de-
velop acute pulmonary inflammation with significant cell in-
filtration in the lung and difficulty in breathing, as shown by
the significant elevation in baseline Penh values (P 
 
 
 
 0.005;
Fig. 3 D). Flow cytometry on bronchoalveolar cells
 
 
 
showed
that the major lung infiltrating cell in CXCL8-treated mice
were neutrophils (Fig. 3 D). Intravenous injection of
r-smCKBP completely ablated all the CXCL8-induced pul-
monary inflammation and changes in lung function (Fig. 3
D). When administered systemically, r-smCKBP is therefore
a highly efficacious inhibitor of chemokine-induced pulmo-
nary inflammation.
Schistosome eggs produce a CKBP for a biological pur-
pose. The schistosome egg is a viable organism and the egg
secretes antigens as it matures within the mammalian host
and stimulates the formation of a granuloma around the
egg. That smCKBP is specifically secreted from live eggs
was shown by the formation of a precipitate around eggs
cultured with anti-smCKBP sera in vitro (Fig. 4 A). Fur-
thermore, smCKBP was detected within the egg itself and
within the granuloma surrounding intact eggs in the liver
or intestine of mice with 
 
S. mansoni
 
 infections (Fig. 4 B),
with no sm-CKBP detected in older granulomas or within
dead eggs (not depicted). The secretion of a CKBP by live
schistosome eggs within the granuloma would suggest that
the smCKBP may block certain chemokines to facilitate
granuloma formation and preferentially alter the cellularity
of the granuloma. To address this we tested the in vivo role
of smCKBP in the setting of the genesis of the egg granu-
loma. Mice were injected intravenously with live schisto-
some eggs and were treated with anti-smCKBP rabbit sera.
This serum specifically recognized smCKBP and no other
schistosome antigens (Fig. 1 D) and in vitro reduced sm-
CKBP ability to block CXCL8 activity (Fig. 5 A). In mice
injected with normal rabbit sera (NRS), there was the char-
acteristic granuloma surrounding eggs in the lungs (Fig. 5
B). In contrast, mice treated with blocking smCKBP sera
had a significant (P 
 
 
 
 0.001), approximately twofold in-
crease in granuloma size relative to the granulomas in ani-
mals treated with NRS (Fig. 5, B and C). The increase in
granuloma size in anti-smCKBP–treated mice was associ-
ated with profound changes in the cell content of the gran-
uloma. Compared with granulomas in NRS-treated mice,
animals with smCKBP blocked had a significant increase in
the proportion of neutrophils and macrophages (P
 
   
 
0.01
and P 
 
 
 
 0.005, respectively) within in the granuloma (Fig.
5, D and E). Despite the marked eosinophil infiltration into
granulomas of anti-smCKBP–treated mice, the numbers of
eosinophils present were significantly reduced (P 
 
 
 
 0.001;
Fig. 5, D and E). Although the formation of the pulmonary
egg granuloma involves the Th2 cytokines IL-4 and IL-13
(12), the modulation of egg granuloma size by anti-
smCKBP treatment was independent of these cytokines,
with an increased size granuloma persisting even when smCKBP
was blocked in double IL-4 and IL-13 gene–deficient mice
(unpublished data). When we injected dead schistosome
Figure 3. r-smCKBP inhibits inflammation in vivo. (A) In an air 
pouch model, r-smCKBP treatment significantly inhibits CXCL8-induced 
neutrophil infiltration (P   0.001). The percentages of neutrophils on 
cytospins are shown as means   SEM (n   4–6) and are representative 
of two separate experiments. (B) r-smCKBP inhibits inflammation in a 
contact hypersensitivity model. DNFB–sensitized mice were injected 
intravenously with r-smCKBP or CRD before application of DNFB solution. 
Data are presented as means   SE of ear thickness (n   6–8 mice). 
Significantly reduced inflammation was observed in mice treated with 
r-smCKBP 24 h after DNFB exposure (P   0.001 by Student’s t test). 
(C) Representative cross sections of ears and cytospins of the pinnae 
infiltrate (H&E stained). Data are representative of three separate experi-
ments. (D) r-smCKBP blocks CXCL8-induced pulmonary neutrophilia. Mice 
were treated intranasally (i.n.) with CXCL8 or PBS or were injected intravenous 
(i.v.) with r-smCKBP or PBS. 18 h later, whole-body plethysmography was 
used to determine lung function (Penh) and bronchoalveolar lavage (BAL) 
fluid recovered for total cell counts and flow cytometry for neutrophil in-
filtration. Statistical values represent differences between CXCL8   PBS–
treated and CXCL8   r-smCKBP–treated groups by Student’s t test. All 
data represent means   SE from four to seven mice per group. Data are 
representative of two separate experiments. 
JEM VOL. 202, November 21, 2005
 
1323
 
BRIEF DEFINITIVE REPORT
 
eggs or studied secondary granulomas in presensitized mice,
blocking smCKBP had no effect on granuloma formation
or cellularity (unpublished data). Therefore, in an experi-
mental granulomatous inflammation model, secretion of
smCKBP by live eggs profoundly modulates the differential
recruitment of cells and the size of the egg granuloma. A
fundamental question that remains to be addressed is what
role does smCKBP have in schistosome infection. To ad-
dress this definitively, the ideal strategy will be to infect
mice with an 
 
S. mansoni
 
 mutant with the smCKBP gene
deleted, as undertaken previously with certain viral CKBPs
(6); however, for technical reasons this is not currently
achievable in schistosomes.
Chemokine inhibitors have been described in viruses (4–
6), whereas the parasite 
 
Toxoplasma gondii
 
 produces a chemo-
kine mimic (13), and recently a 
 
Staphylococcus aureus
 
 protein
has been shown to inhibit other leukocyte chemoattractants
(14). We now show that schistosome eggs secrete a molecule
that blocks activity of certain chemokines both in vitro and in
vivo. smCKBP is the first CKBP identified in a human patho-
gen and is the only one identified in a parasite to date. sm-
CKBP is a potent suppressor of inflammatory responses in
acute murine inflammation models. This study highlights the
potential for using pathogen-derived immune modulating
molecules as novel therapeutics for inflammatory diseases.
 
MATERIALS AND METHODS
 
Parasite antigen preparations
 
S. mansoni
 
 eggs were obtained as described previously(15). For in vitro cultures
of live eggs and preparation of ES, all reagents were sterile and endotoxin free,
and procedures were performed under aseptic conditions. Cercariae homoge-
nates and secretions or homogenates of schistosome worms and schistosomula
were prepared as described previously (16). S. haematobium egg antigens were
obtained from the Schistosome Biological Supply Center, and S. japonicum
eggs were provided by M. Johansen (Danish Bilharziasis Laboratory, Charlot-
Figure 4. Secretion of smCKBP from live eggs in vitro and in vivo. 
(A) Precipitate formation (arrows) around live eggs cultured in vitro with 
anti-smCKBP sera but not NRS. (B) Detection of smCKBP (brown stain) 
within the granulomas surrounding eggs in liver or intestines of infected 
mice. Bar, 50  m.
Figure 5. Blocking smCKBP in vitro increases the pulmonary granu-
lomatous inflammation to live eggs. (A) Rabbit anti-smCKBP sera dose-
dependently blocks r-smCKBP activity in vitro. Different dilutions, in triplicate, 
of NRS (open circles and continuous line) and anti-smCKBP sera (red filled 
circles and line) were incubated with r-smCKBP before addition of 125I-CXCL8. 
Samples were then tested in a U937 cell binding assay. Data are presented 
relative to 100% blocking of 125I-CXCL8 cell binding by r-smCKBP. (B) Sections 
of lungs showing granuloma around eggs (arrow) in lungs of mice treated 
with NRS or anti-smCKBP sera as stained by H&E. Bar, 50  m. (C) Size of 
egg granuloma in lungs of mice treated with NRS or anti-smCKBP sera. The 
values shown represent means   SD. (D) High magnification of cells within 
granuloma around eggs (top right, arrows) in lungs of mice treated with 
NRS or anti-smCKBP sera. Bar, 10  m. (E) Cell composition of pulmonary 
granulomas around eggs in lungs of mice treated with NRS or anti-smCKBP 
sera. Data represent means   SD from six mice per group and are 
representative of two separate experiments. Student’s t test was used 
to test for statistical differences between groups, and p-values are shown.SCHISTOSOMES SECRETE A CHEMOKINE BINDING PROTEIN | Smith et al. 1324
tenlund, Denmark). All batches of antigen were tested for endotoxin contami-
nation and confirmed to have  1 EU/mg of protein (Biowhittaker).
Chemokine assays
Radioiodinated recombinant human chemokines were obtained from Perkin-
Elmer or GE Healthcare. Recombinant chemokines were purchased from
PeproTech. Chemokine cross-linking and cell binding assays were performed
as described previously (17). For cell migration assays, 100–1,000 ng/ml
CXCL8 and smCKBP were mixed together for 15 min at 37 C before addi-
tion to transwell migration chambers (ChemoTX), and neutrophils purified
from human PBMCs were added. Triplicate wells were used per dilution and
negative (no CXCL8, blank) and positive (CXCL8, alone) controls were in-
cluded. 100 nM of the chemotactic peptide n-FMLP was also used as a
nonchemokine inducer of neutrophil migration. Data are presented as mean
cells migrated   SD from triplicate wells. Ca2  flux after CCL5 activation of
cells was determined as previously described (18). PBMCs were isolated from
three donors and were labeled with Fluo-4 AM (Invitrogen). PBMCs were
activated by 100 ng/ml CCL5 or CCL5 that had been preincubated with
r-smCKBP or CRD. Ca2  flux by activated cells was analyzed using a FACS-
can and Cell Quest software (Becton Dickinson). Data are presented as the
mean percent inhibition of total CCL5-elicited Ca2  flux.
Isolation, cloning, and expression of smCKBP
ES were fractionated by cation exchange chromatography and eluted using
an NaCl gradient. Purified smCKBP was resolved by SDS-PAGE, and both
bands were excised for mass spectrometry analysis using an LCQ Classic
(ThermoFinnigan) with a nanospray interface (Protana). The sequences ob-
tained were used in conventional database searches for sequence homology.
An EST (available from GenBank/EMBL/DDBJ under accession no.
AI820476) clone from an S. mansoni egg cDNA library, predicted to encode
an open reading frame with sequence similarity to an smCKBP peptide, was
provided by G. Oliveira, Centro de Pesquisas Rene Rachou-Fiocruz, Belo
Horizonte, Brazil. The smCKBP gene was PCR amplified, cloned into a
baculovirus expression vector (pBAC-1) under the control of the strong
polyhedrin promoter, cloned into a vaccinia virus expression vector
(pMJ601) under the control of a synthetic late promoter, and fused to a
COOH-terminal 6xHis tag, with or without CD33 signal peptide. Recom-
binant viruses were constructed according to standard procedures. The
r-smCKBP protein was secreted from Spodoptera frugiperda insect cells and
BSC1 cells infected with recombinant baculovirus and vaccinia virus, re-
spectively, independent of CD33. r-smCKBP expressed from baculovirus-
infected cells was purified using affinity chromatography in nickel chelate
columns according to standard procedures. A construct comprising the two
NH2-terminal cysteine-rich domains of the tumor necrosis factor receptor
CrmD from ectromelia virus (CRD) (9) was produced and purified in the
same manner as r-smCKBP and used as a control baculovirus-expressed and
6xHis-tagged purified protein for functional studies. All batches of purified
r-smCKBP and CRD were tested for endotoxin contamination and con-
firmed to have  1EU/mg of protein (Biowhittaker).
smCKBP antisera
Rabbit sera against r-smCKBP was prepared by Harlan Sera Labs. To test
the ability of the anti-smCKBP to block the chemokine binding activity of
smCKBPs, U937 cells were used in 125I-chemokine cell binding assays. A
range of dilutions of the anti-smCKBP sera or NRS were preincubated
with r-smCKBP. These sera   smCKBP solutions were added to 125I-
CXCL8 for 1 h before addition to U937 cells. Bound 125I-chemokine was
determined by phthalate oil centrifugation (19)
Detection of smCKBP gene in schistosome cercerial DNA
A Puerto Rican strain of S. mansoni was maintained by passage in CD1 strain
mice and albino Biomphalaria glabrata snails. All animal experiments were per-
formed in compliance with Irish Department of Health and Children regula-
tions. Cercariae were shed from individual patently infected snails, and genomic
DNA was isolated (20). DNA was isolated from mouse tail snips using the Wiz-
ard SV Genomic DNA Purification System (Promega). Based on the smCKBP
sequence, specific primers were designed and used in PCR. The band detected
in cercariae DNA was excised from gels, purified with a gel extraction kit
(QIAquick; QIAGEN), and sequenced to confirm it was smCKBP.
Egg pulmonary granuloma model
Live eggs were isolated from the livers of infected mice as described previ-
ously (15). BALB/c strain mice, or double IL-4   IL-13–deficient mice
(12), were injected intravenously with 5,000 live eggs. On day 0 and every
3 d after, mice were injected intraperitoneally with NRS or anti-smCKBP
sera. Mice were killed on day 15 and lungs were removed. Lungs were
fixed in formaldehyde saline and processed for histology. The size (volume
assuming a sphere) and percentage of eosinophils, neutrophils, and mac-
rophages within the granuloma was evaluated in  30 individual egg granu-
lomas per mouse, as described previously (21). Dead eggs were prepared by
storing live eggs frozen and were used in the above protocol. Secondary
granulomas were elicited as described previously, with a modification that
live eggs were used in the secondary challenge (21).
Air pouch model
Dorsal air pouches were induced in mice using previously described methods
(22). In brief, 4 ml of sterile-filtered air was injected subcutaneously into the
back of female BALB/c mice, and the pouch was reinflated with 3 ml of
sterile air 3 d later. The dorsal air pouches of groups of 5–6 mice were either
injected with 1 ml PBS or 1 ml PBS with 1  g CXCL8 3 d later. At the
same time, mice were injected intravenously with 200  l PBS or 200  l PBS
containing 20  g of r-smCKBP or OVA. Mice were killed and air pouches
were lavaged with PBS 3 h later. The aspirate was centrifuged and cells were
counted. Differential counts were performed on stained cytospins.
Contact hypersensitivity
Female BALB/c mice (6–8 wk old) were sensitized by topical application of
0.5% 2,4-dintrofluorobenzene (DNFB; Sigma-Aldrich) to the shaved abdo-
men. After 5 d, 0.02% DNFB was added to the right ear and the vehicle
(acetone/olive oil   4:1) was applied to the left ear. r-smCKBP or OVA
(10  g in 100  l) were injected intravenously into mice before the applica-
tion of DNFB to the ears. Ear swelling was measured with a dial thickness
gauge (Mitutoyo) 24 h after application of DNFB. Ears were removed from
mice, fixed, and cross sections of ears were hematoxylin and eosin (H&E)–
stained. The cellular infiltrate of the ear pinnae were isolated and counted,
and differential cell counts were performed on DiffQuik-stained cytospins.
CXCL8-induced pulmonary neutrophilia model
25  g CXCL8 was administered intranasally by droplet to BALB/c mice (23).
Mice were then injected intravenously with 200  l of 20  g r-smCKBP or
CRD. 18 h later, lung function was analyzed as described in the next section.
Lung function studies
Unrestrained conscious animals were subjected to barometric whole-body
plethysmography to determine lung function (Emka). Mice were acclima-
tized to the chamber, and breathing was recorded over 6 min. Baseline en-
hanced pause (Penh) was determined as a measurement of lung function
(24). Data are means of 4–7 mice per group, and all experiments were re-
peated at least twice. Bronchoalveolar lavage, cytospins, flow cytometry for
neutrophils (non–B cells, non–T cells, Gr-1  cells, and Mac-1  cells), and
quantification of myeloperoxidase were by standard methods.
Detection of smCKBP secretion from eggs
Circumoval precipitin test. S. mansoni eggs were isolated from the livers
of infected mice as previously described (15). Live eggs were cultured at
37 C with NRS or anti-smCKBP sera. Eggs were examined for the pres-
ence of precipitates around eggs 24–48 h later.
Immunocytochemistry. Liver and intestines were isolated from infected
mice and frozen in OCT compound. Tissue was cryosectioned. Slides wereJEM VOL. 202, November 21, 2005 1325
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probed with NRS or anti-smCKBP sera. Detection was with horseradish
peroxidase–conjugated anti–rabbit-IgG (Sigma-Aldrich). Diaminobenzidine
was used as substrate, and slides were counterstained with H&E.
Statistical analysis
Significant differences between groups were analyzed by Student’s t test.
P   0.05 was considered significant.
Online supplemental material
Fig. S1 shows that smCKBPs isolated from S. mansoni ES and soluble egg an-
tigens can bind CXCL8. In Fig. S2, r-smCKBP-2 does not induce basophil
degranulation. In Fig. S3, r-smCKBP does not alter disease in experimental
autoimmune encephalomyelitis or in collagen-induced arthritis. Supplemental
Materials and methods are also included. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20050955/DC1.
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